Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.

ABSTRACT:

Introduction

Hepatitis C is a disease with a significant global impact. Over the last several years, the treatment of the disease has been revolutionized. Therapy has transformed over the last several years with the approval of second generation direct acting antivirals, and currently utilized medications for the treatment of hepatitis C are significantly more efficacious with better safety profiles than previously approved treatments. Treatment for individuals who have failed therapy on direct acting antivirals has, until recently, been complex and difficult to treat, but the approval of sofosbuvir/velpatasvir/voxilaprevir represents a new therapeutic option for these individuals. Areas covered: Sofosbuvir/velpatasvir/voxilaprevir is a recently approved therapeutic combination for

SUBMITTER: Cory TJ 

PROVIDER: S-EPMC6015630 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature